Published in Gastrointest Cancer Res on March 01, 2008
miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res (2011) 1.51
Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist (2010) 1.16
Rapid induction of orthotopic hepatocellular carcinoma in immune-competent rats by non-invasive ultrasound-guided cells implantation. BMC Gastroenterol (2010) 0.97
Baicalin induces apoptosis in hepatic cancer cells in vitro and suppresses tumor growth in vivo. Int J Clin Exp Med (2015) 0.86
Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma. World J Hepatol (2010) 0.80
Long-term survival of a HCC-patient with severe liver dysfunction treated with sorafenib. World J Hepatol (2010) 0.79
Nitidine chloride inhibits hepatic cancer growth via modulation of multiple signaling pathways. BMC Cancer (2014) 0.75
Responding to the rising incidence of hepatocellular carcinoma with targeted therapy. Gastrointest Cancer Res (2008) 0.75
THE HERBAL MIXTURE XIAO-CHAI-HU TANG (XCHT) INDUCES APOPTOSIS OF HUMAN HEPATOCELLULAR CARCINOMA HUH7 CELLS IN VITRO AND IN VIVO. Afr J Tradit Complement Altern Med (2017) 0.75
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med (1999) 17.03
Estimating the world cancer burden: Globocan 2000. Int J Cancer (2001) 16.92
Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis (1999) 12.31
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol (2004) 9.73
Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer (1985) 7.67
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 6.95
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology (1998) 6.47
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol (2004) 5.12
BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst (2006) 3.61
Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology (2000) 3.30
Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol (2006) 3.09
Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol (2003) 2.87
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst (2005) 2.73
Alcohol and hepatocellular carcinoma. Gastroenterology (2004) 2.61
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol (2005) 2.56
International trends and patterns of primary liver cancer. Int J Cancer (2001) 2.50
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 2.38
A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. J Hepatol (1999) 2.38
Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol (2005) 1.87
Induction of remission in hepatocellular carcinoma with doxorubicin. Lancet (1978) 1.86
Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol (1997) 1.85
Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer (1988) 1.83
Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res (1999) 1.77
Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology (2004) 1.73
Obesity and mortality. N Engl J Med (2005) 1.65
HBV induced carcinogenesis. J Clin Virol (2005) 1.56
The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol (2001) 1.48
EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol (2005) 1.35
Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication. Cancer (1975) 1.29
Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein. Oncogene (2001) 1.29
Treatment options in metastatic renal carcinoma: an embarrassment of riches. J Clin Oncol (2005) 1.28
Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin Cancer Res (2005) 1.19
Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. Liver (1997) 1.14
Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer (1978) 1.13
Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer (1985) 1.12
Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. Cancer (1984) 1.11
Primary liver cancer. An Eastern Cooperative Oncology Group Trial. Cancer (1984) 1.10
A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United States. Cancer (1977) 1.08
Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep (1984) 1.05
Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol (2002) 0.97
Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study. AJR Am J Roentgenol (2004) 0.89
Adriamycin therapy in American patients with hepatocellular carcinoma. Cancer Treat Rep (1977) 0.89
Epidermal growth factor receptor in human hepatocellular carcinoma. Cancer Detect Prev (1997) 0.87
Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin. Cancer (1983) 0.86
Further experience in treating patients with hepatocellular carcinoma in Uganda. Cancer (1980) 0.85
Towards global control of liver cancer? Semin Cancer Biol (1998) 0.84
Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. Int J Clin Pharmacol Ther (2004) 0.84
A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma. Cancer (1999) 0.83
Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma. Invest New Drugs (2006) 0.77
[Hepatocellular carcinoma with cirrhosis: treatment with doxorubicin. Phase II evaluation]. Bull Cancer (1984) 0.77
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 6.95
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA (2010) 4.71
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol (2010) 4.69
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol (2006) 4.27
Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res (2010) 3.24
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol (2009) 2.94
Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA (2007) 2.84
Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol (2010) 2.81
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol (2011) 2.76
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol (2008) 2.74
Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol (2012) 2.74
Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA (2008) 2.67
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol (2006) 2.51
Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol (2009) 2.50
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res (2011) 2.40
Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol (2009) 2.11
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res (2009) 2.02
Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol (2008) 1.92
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J Clin Oncol (2005) 1.82
Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol (2002) 1.78
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol (2014) 1.76
The camptothecins. Lancet (2003) 1.68
Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg (2002) 1.65
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol (2013) 1.62
Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol (2008) 1.61
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol (2014) 1.59
Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg (2012) 1.58
Evolving treatment of advanced colon cancer. Annu Rev Med (2009) 1.56
Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol (2008) 1.54
Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. Cancer (2011) 1.53
Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer (2008) 1.53
Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol (2007) 1.52
Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. Ann Surg Oncol (2002) 1.50
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs (2007) 1.47
An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist (2011) 1.44
Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors. Oncology (2011) 1.44
Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol (2009) 1.38
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.38
BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer (2014) 1.32
Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol (2011) 1.31
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.24
Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol (2009) 1.24
Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Natl Cancer Inst (2012) 1.20
Role of expression profiling in carcinoma of unknown primary remains unknown. J Clin Oncol (2013) 1.20
Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy. Oncologist (2011) 1.20
Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. Hum Pathol (2012) 1.20
A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS One (2012) 1.15
Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Clin Cancer Res (2005) 1.15
Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803. Cancer (2010) 1.14
A randomized controlled trial of a cardiopulmonary resuscitation video in advance care planning for progressive pancreas and hepatobiliary cancer patients. J Palliat Med (2013) 1.14
Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res (2013) 1.13
A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer (2012) 1.13
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst (2011) 1.12
Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. N Engl J Med (2014) 1.07
Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst (2011) 1.06
Adjuvant therapy of colon cancer: current status and future directions. Cancer J (2007) 1.06
Costs and trends in pancreatic cancer treatment. Cancer (2012) 1.04
Palliative care in the outpatient oncology setting: evaluation of a practical set of referral criteria. J Oncol Pract (2011) 1.04
Augmenting advance care planning in poor prognosis cancer with a video decision aid: a preintervention-postintervention study. Cancer (2012) 1.04
Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Canc Netw (2014) 1.01
Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. Radiother Oncol (2013) 1.00
Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys (2005) 0.99
Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome. Ann Surg Oncol (2012) 0.99
Recurrence rates and prognostic factors in ypN0 rectal cancer after neoadjuvant chemoradiation and total mesorectal excision. Ann Surg Oncol (2011) 0.98
Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol (2006) 0.98
Evaluation of ¹⁸F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis. Ann Surg Oncol (2011) 0.97
Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. Nat Clin Pract Oncol (2009) 0.96
KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. Oncologist (2011) 0.96
Hepatocellular carcinoma in two patients with cardiac cirrhosis. Eur J Gastroenterol Hepatol (2010) 0.95
Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Am J Clin Oncol (2011) 0.92
Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. Cancer (2006) 0.92
Refinement of adjuvant therapy for pancreatic cancer. JAMA (2010) 0.92
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst (2013) 0.92
Biliary tract cancers: current concepts and controversies. Expert Opin Pharmacother (2005) 0.91
p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. Clin Cancer Res (2009) 0.90
A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. Pancreatology (2009) 0.90
Collision tumor of the large bowel in the context of advanced pregnancy and ulcerative colitis. Clin Colorectal Cancer (2008) 0.90
Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol (2010) 0.89
Postoperative outcomes following pancreaticoduodenectomy: how should age affect clinical practice? World J Surg Oncol (2013) 0.88
Biomarkers in colorectal cancer: added value or just added expense? Expert Rev Mol Diagn (2008) 0.87
Addition of octreotide functional imaging to cross-sectional computed tomography or magnetic resonance imaging for the detection of neuroendocrine tumors: added value or an anachronism? J Clin Oncol (2010) 0.87
Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res (2013) 0.86
Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. Int J Radiat Oncol Biol Phys (2010) 0.86
Antibody-based therapies for colorectal cancer. Oncologist (2005) 0.85
Serum 25-hydroxy vitamin D and survival in advanced colorectal cancer: a retrospective analysis. Nutr Cancer (2015) 0.84
Building on Individual, State, and Federal Initiatives for Advance Care Planning, an Integral Component of Palliative and End-of-Life Cancer Care. J Oncol Pract (2011) 0.84
Doxorubicin and sorafenib for treatment of advanced hepatocellular cancer. Gastroenterology (2011) 0.83
FDG-PET assessment of rectal cancer response to neoadjuvant chemoradiotherapy is not associated with long-term prognosis: a prospective evaluation. Dis Colon Rectum (2012) 0.82
Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature. Am J Clin Oncol (2003) 0.82
Irinotecan (Campto) in the treatment of pancreatic cancer. Expert Rev Anticancer Ther (2003) 0.82
Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer. Cancer Invest (2003) 0.81
Indications for neoadjuvant, adjuvant, and palliative chemotherapy in the treatment of biliary tract cancers. Surg Oncol Clin N Am (2009) 0.81
Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. Cancer (2012) 0.80
Electronic Chemotherapy Order Entry: A Major Cancer Center's Implementation. J Oncol Pract (2011) 0.80
A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma. J Gastrointest Cancer (2011) 0.80
Evolving panorama of treatment for metastatic pancreas adenocarcinoma. J Clin Oncol (2013) 0.79